Financial Performance - Total revenue for Q3 2024 reached ¥690,041,603.94, an increase of 14.09% compared to the same period last year[2] - Net profit attributable to shareholders was ¥66,939,689.71, reflecting a significant increase of 55.51% year-over-year[2] - The net profit excluding non-recurring gains and losses was ¥52,743,061.05, up 123.78% from the previous year[2] - Basic earnings per share for the quarter were ¥0.33, representing a 57.14% increase compared to the same quarter last year[2] - The net profit for Q3 2024 was CNY 251,937,817.59, an increase from CNY 242,376,937.02 in Q3 2023, representing a growth of approximately 2.5%[21] - The total profit for Q3 2024 reached CNY 294,957,750.19, compared to CNY 276,301,297.27 in the same period last year, marking an increase of about 6.2%[21] - Basic earnings per share for Q3 2024 were CNY 1.24, up from CNY 1.16 in Q3 2023, reflecting a growth of approximately 6.9%[22] - Operating income for Q3 2024 was CNY 294,753,492.12, slightly higher than CNY 280,938,487.73 in Q3 2023, reflecting a growth of about 4.0%[21] Assets and Liabilities - Total assets as of September 30, 2024, amounted to ¥6,474,130,966.28, a growth of 3.68% from the end of the previous year[2] - The company's total liabilities increased to ¥1.73 billion from ¥1.34 billion, reflecting a growth of approximately 29.3%[19] - As of September 30, 2024, total assets amounted to ¥6.47 billion, an increase from ¥6.24 billion at the beginning of the year[19] Cash Flow - The company’s cash flow from operating activities for the year-to-date was ¥435,875,379.93, an increase of 17.84%[2] - Cash flow from operating activities for Q3 2024 was CNY 435,875,379.93, compared to CNY 369,874,076.42 in Q3 2023, indicating an increase of around 17.8%[23] - The cash and cash equivalents at the end of Q3 2024 amounted to CNY 1,682,965,410.24, up from CNY 1,054,257,326.80 at the end of Q3 2023, representing a significant increase of approximately 59.5%[24] - The net cash flow from investing activities for the current period was -157,365,720.23 RMB, a decrease of 52.51% compared to the previous period's -331,391,837.61 RMB, mainly due to reduced payments for fixed asset purchases[7] - The net cash flow from financing activities was -36,851,886.09 RMB, showing an improvement of 89.61% from -354,777,965.82 RMB in the previous period, primarily due to decreased payments for stock repurchases[7] - The net cash flow from investing activities for Q3 2024 was -CNY 157,365,720.23, an improvement from -CNY 331,391,837.61 in Q3 2023[24] - The net cash flow from financing activities for Q3 2024 was -CNY 36,851,886.09, compared to -CNY 354,777,965.82 in Q3 2023, showing a significant reduction in outflows[24] Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,353, with the largest shareholder, Changsha Medical Investment Co., Ltd., holding 40.69% of shares[8] - The top ten shareholders collectively hold significant stakes, with the largest shareholder owning 85,079,923 shares, while the second and third largest shareholders each hold 12,114,881 shares[8] - The company plans to distribute a cash dividend of 12 RMB per 10 shares, totaling an estimated 244,437,262.80 RMB (including tax) for the 2023 fiscal year[13] - For the 2024 semi-annual profit distribution, the company intends to distribute a cash dividend of 6 RMB per 10 shares, amounting to an estimated 122,037,041.40 RMB (including tax)[14] - The company repurchased and canceled 146,250 restricted shares as part of its stock incentive plan, reducing the total restricted shares to 255,937[12] - The company has a repurchase account holding 5,696,931 shares, representing 2.72% of the total share capital, ranking fifth among all shareholders[10] - The company has not reported any changes in the top ten shareholders due to securities lending activities during the reporting period[11] - The company repurchased 1,494,562 shares, accounting for 0.71% of the total share capital, with a total transaction amount of approximately ¥49.99 million[16] Expenses and Costs - The company reported a 35.49% increase in sales expenses, totaling ¥711,660,470.44, due to increased marketing and promotional activities[6] - Total operating costs increased to ¥1.97 billion from ¥1.87 billion, reflecting a rise of about 5.06%[20] - Research and development expenses for the current period were ¥69.41 million, down from ¥79.24 million, indicating a decrease of about 12.3%[20] Goodwill and Investments - The company’s goodwill increased by 50.05% to ¥363,720,043.92, primarily due to acquisitions made during the period[5] - The company reported a significant increase in goodwill, rising to ¥363.72 million from ¥242.41 million, an increase of approximately 50%[18] - Investment income surged to ¥15,042,833.01, marking a 1,485.88% increase compared to the previous period[6] - The company's long-term equity investments increased slightly to ¥65.39 million from ¥64.93 million, showing a growth of about 0.71%[17]
可孚医疗(301087) - 2024 Q3 - 季度财报